 Treatment advanced neuroblastoma meta-iodobenzylguanidine February December children advanced neuroblastoma meta-Iodobenzylguanidine Thirteen children resistant first-line therapy local relapse fourteen disseminated relapse bone marrow infiltration child resistance first-line therapy local relapse total courses doses GBq median GBq child courses courses courses courses course common toxic effect thrombocytopenia platelet level evaluable courses leukocyte count major responses complete months minor responses months Responses children lesion residual primary tumor children relapse Further studies role meta-Iodobenzylguanidine treatment neuroblastoma